Literature DB >> 32955488

Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder.

Matthew K Schindler1,2, Stefania Pittaluga3, Yoshimi Enose-Akahata4, Helen C Su5, V Koneti Rao6, Amy Rump6, Steven Jacobson4, Irene Cortese1, Daniel S Reich1,2, Gulbu Uzel6.   

Abstract

BACKGROUNDCytotoxic T lymphocyte antigen 4 (CTLA4) is essential for immune homeostasis. Genetic mutations causing haploinsufficiency (CTLA4h) lead to a phenotypically heterogenous, immune-mediated disease that can include neuroinflammation. The neurological manifestations of CTLA4h are poorly characterized.METHODSWe performed an observational natural history study of 50 patients with CTLA4h who were followed at the NIH. We analyzed clinical, radiological, immunological, and histopathological data.RESULTSEvidence for neuroinflammation was observed in 32% (n = 16 of 50) of patients in this cohort by magnetic resonance imaging (MRI) and/or by cerebrospinal fluid analysis. Clinical symptoms were commonly absent or mild in severity, with headaches as the leading complaint (n = 13 of 16). The most striking findings were relapsing, large, contrast-enhancing focal lesions in the brain and spinal cord observed on MRI. We detected inflammation in the cerebrospinal fluid and leptomeninges before the parenchyma. Brain biopsies of inflammatory lesions from 10 patients showed perivascular and intraparenchymal mixed cellular infiltrates with little accompanying demyelination or neuronal injury.CONCLUSIONSNeuroinflammation due to CTLA4h is mediated primarily by an infiltrative process with a distinct and striking dissociation between clinical symptoms and radiological findings in the majority of patients.FUNDINGNIAID, NIH, Division of Intramural Research, NINDS, NIH, Division of Intramural Research, and the National Multiple Sclerosis Society-American Brain Foundation.TRIAL REGISTRATIONClinicalTrials.gov NCT00001355.

Entities:  

Keywords:  Autoimmune diseases; Genetic diseases; Inflammation; Neuroimaging; Neuroscience

Year:  2020        PMID: 32955488      PMCID: PMC7524497          DOI: 10.1172/JCI135947

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Authors:  Tanya J Williams; David R Benavides; Kelly-Ann Patrice; Josep O Dalmau; Alexandre Leon Ribeiro de Ávila; Dung T Le; Evan J Lipson; John C Probasco; Ellen M Mowry
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

Authors:  Bing Liao; Sheetal Shroff; Carlos Kamiya-Matsuoka; Sudhakar Tummala
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

4.  Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells.

Authors:  C A Chambers; T J Sullivan; J P Allison
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

5.  Peripheral neuropathy associated with ipilimumab: a report of 2 cases.

Authors:  Iyavut Thaipisuttikul; Paul Chapman; Edward K Avila
Journal:  J Immunother       Date:  2015 Feb-Mar       Impact factor: 4.456

6.  Neurological immune-related adverse events of ipilimumab.

Authors:  Ilja Bot; Christian U Blank; Willem Boogerd; Dieta Brandsma
Journal:  Pract Neurol       Date:  2013-03-13

7.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.

Authors:  Hye Sun Kuehn; Weiming Ouyang; Bernice Lo; Elissa K Deenick; Julie E Niemela; Danielle T Avery; Jean-Nicolas Schickel; Dat Q Tran; Jennifer Stoddard; Yu Zhang; David M Frucht; Bogdan Dumitriu; Phillip Scheinberg; Les R Folio; Cathleen A Frein; Susan Price; Christopher Koh; Theo Heller; Christine M Seroogy; Anna Huttenlocher; V Koneti Rao; Helen C Su; David Kleiner; Luigi D Notarangelo; Yajesh Rampertaap; Kenneth N Olivier; Joshua McElwee; Jason Hughes; Stefania Pittaluga; Joao B Oliveira; Eric Meffre; Thomas A Fleisher; Steven M Holland; Michael J Lenardo; Stuart G Tangye; Gulbu Uzel
Journal:  Science       Date:  2014-09-11       Impact factor: 47.728

8.  Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.

Authors:  Desirée Schubert; Claudia Bode; Rupert Kenefeck; Tie Zheng Hou; Lucy S K Walker; David M Sansom; Bodo Grimbacher; James B Wing; Alan Kennedy; Alla Bulashevska; Britt-Sabina Petersen; Alejandro A Schäffer; Björn A Grüning; Susanne Unger; Natalie Frede; Ulrich Baumann; Torsten Witte; Reinhold E Schmidt; Gregor Dueckers; Tim Niehues; Suranjith Seneviratne; Maria Kanariou; Carsten Speckmann; Stephan Ehl; Anne Rensing-Ehl; Klaus Warnatz; Mirzokhid Rakhmanov; Robert Thimme; Peter Hasselblatt; Florian Emmerich; Toni Cathomen; Rolf Backofen; Paul Fisch; Maximilian Seidl; Annette May; Annette Schmitt-Graeff; Shinji Ikemizu; Ulrich Salzer; Andre Franke; Shimon Sakaguchi
Journal:  Nat Med       Date:  2014-10-20       Impact factor: 53.440

9.  Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Authors:  M Schiff; M Keiserman; C Codding; S Songcharoen; A Berman; S Nayiager; C Saldate; T Li; R Aranda; J-C Becker; C Lin; P L N Cornet; M Dougados
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103

Review 10.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775

View more
  3 in total

1.  Rapid Emergence of T Follicular Helper and Germinal Center B Cells Following Antiretroviral Therapy in Advanced HIV Disease.

Authors:  Chun-Shu Wong; Clarisa M Buckner; Silvia Lucena Lage; Luxin Pei; Felipe L Assis; Eric W Dahlstrom; Sarah L Anzick; Kimmo Virtaneva; Adam Rupert; Jeremy L Davis; Ting Zhou; Elizabeth Laidlaw; Maura Manion; Frances Galindo; Megan Anderson; Catherine A Seamon; Michael C Sneller; Andrea Lisco; Claire Deleage; Stefania Pittaluga; Susan Moir; Irini Sereti
Journal:  Front Immunol       Date:  2021-12-01       Impact factor: 7.561

Review 2.  Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.

Authors:  Nicholas L Bayless; Jeffrey A Bluestone; Samantha Bucktrout; Lisa H Butterfield; Elizabeth M Jaffee; Christian A Koch; Bart O Roep; Arlene H Sharpe; William J Murphy; Alexandra-Chloé Villani; Theresa L Walunas
Journal:  J Immunother Cancer       Date:  2021-09       Impact factor: 12.469

3.  Immunopathogenic CSF TCR repertoire signatures in virus-associated neurologic disease.

Authors:  Satoshi Nozuma; Yoshimi Enose-Akahata; Kory R Johnson; Maria Chiara Monaco; Nyater Ngouth; Abdel Elkahloun; Joan Ohayon; Jun Zhu; Steven Jacobson
Journal:  JCI Insight       Date:  2021-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.